Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Completed 5

Sponsor Class

OTHER 66INDUSTRY 34NIH 5FED 3NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 4Gynecologic 1

Conditions

Melanoma 2Carcinoma, Basal Cell 2Uterine Cervical Dysplasia 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 385Specimen Handling 371Magnetic Resonance Spectroscopy 325Radiotherapy 306Biopsy 269Cisplatin 257Carboplatin 253Paclitaxel 235Doxorubicin 226Fluorouracil 200Etoposide 197Vincristine 182Bevacizumab 180Filgrastim 170Gemcitabine 163Leucovorin 149Cytarabine 144aldesleukin 140Taxes 127Docetaxel 122Oxaliplatin 113Chemotherapy, Adjuvant 113fludarabine phosphate 111Rituximab 107Methotrexate 107Radiation 106Bortezomib 105Prednisone 102Irinotecan 100Dexamethasone 100

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
NIH × Interventional × Imiquimod × Clear all
NCT03196180 2025-04-08

Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Completed
13 enrolled 10 charts
Gynecologic

Uterine Cervical Dysplasia

NCT00453050 2015-05-06

Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin

National Cancer Institute (NCI)

Phase 1 Completed
11 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00066872 2013-09-17

Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer

National Cancer Institute (NCI)

Phase 3 Completed
500 enrolled
Dermatologic

Carcinoma, Basal Cell

NCT00079300 2013-04-26

Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
Dermatologic

Carcinoma, Basal Cell

NCT00273910 2012-10-19

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
104 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡